TrialVaccine2025

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.

Vu Dinh Thiem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.